MET and Small-Cell Lung Cancer
Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options ar...
Main Authors: | Francesco Gelsomino, Giulio Rossi, Marcello Tiseo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/6/4/2100 |
Similar Items
-
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trialResearch in context
by: Yongfeng Yu, et al.
Published: (2023-05-01) -
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
by: Max Hardy-Werbin, et al.
Published: (2019-09-01) -
Targeting the hedgehog pathway in MET mutation cancers and its effects on cells associated with cancer development
by: Yifan Du, et al.
Published: (2023-11-01) -
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
by: Gianluca Spitaleri, et al.
Published: (2023-09-01) -
Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer
by: Xiaoqing YU, et al.
Published: (2017-04-01)